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Background: Infected necrotising pancreatitis is a potentially lethal disease that nearly always requires intervention.
Traditionally, primary open necrosectomy has been the treatment of choice. In recent years, the surgical step-up
approach, consisting of percutaneous catheter drainage followed, if necessary, by (minimally invasive) surgical
necrosectomy has become the standard of care. A promising minimally invasive alternative is the endoscopic
transluminal step-up approach. This approach consists of endoscopic transluminal drainage followed, if necessary,
by endoscopic transluminal necrosectomy. We hypothesise that the less invasive endoscopic step-up approach is
superior to the surgical step-up approach in terms of clinical and economic outcomes.
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Methods/Design: The TENSION trial is a randomised controlled, parallel-group superiority multicenter trial. Patients
with (suspected) infected necrotising pancreatitis with an indication for intervention and in whom both treatment
modalities are deemed possible, will be randomised to either an endoscopic transluminal or a surgical step-up
approach. During a 4 year study period, 98 patients will be enrolled from 24 hospitals of the Dutch Pancreatitis
Study Group. The primary endpoint is a composite of death and major complications within 6 months following
randomisation. Secondary endpoints include complications such as pancreaticocutaneous fistula, exocrine or
endocrine pancreatic insufficiency, need for additional radiological, endoscopic or surgical intervention, the need for
necrosectomy after drainage, the number of (re-)interventions, quality of life, and total direct and indirect costs.
Discussion: The TENSION trial will answer the question whether an endoscopic step-up approach reduces the
combined primary endpoint of death and major complications, as well as hospital stay and related costs compared
with a surgical step-up approach in patients with infected necrotising pancreatitis.
Keywords: Acute pancreatitis, Necrotising, Treatment, Drainage, Trial, Endoscopy, Minimally invasive, Surgery,
Necrosectomy, PancreasBackground
Acute pancreatitis is a common and potentially lethal
disease. About 20% of patients develop necrosis of the
pancreatic parenchyma and/or extrapancreatic fat tis-
sue [1,2]. Necrotising pancreatitis is associated with
pancreatic and/or peripancreatic collections with fluid
and necrosis. As long as these collections remain sterile,
treatment is generally conservative. However, in one
third of patients infection of necrosis occurs. Infected
necrosis is associated with a mortality rate of around
30% (range 12-39%) [1,3-5] and is virtually always an
indication for invasive treatment.
The current treatment of choice is a surgical step up
approach [6]. This approach consists of percutaneous
catheter drainage, if necessary, followed by surgical
necrosectomy. A recent randomised controlled trial
demonstrated that this approach reduces death and
major complications from 69% to 40% compared with
primary open necrosectomy [2]. Furthermore, catheter
drainage obviates the need of surgical necrosectomy
and associated complications in 35% of patients [2].
Although this trial did not compare minimally invasive
necrosectomy to open necrosectomy it did show superior-
ity of the ‘surgical step-up approach’ to primary open
necrosectomy. A promising alternative gaining world-
wide popularity is endoscopic transluminal drainage
and necrosectomy. These procedures can be performed
under procedural sedation, thereby avoiding general
anaesthesia [7]. Furthermore, abdominal wall incision
with its related surgical stress and complications such as
incisional hernia, pancreatic fistula and wound infection,
are evaded. The endoscopic technique can also be applied
in a step-up fashion, consisting of endoscopic translumi-
nal drainage (ETD) followed, if necessary, by endoscopic
transluminal necrosectomy (ETN). In recent years, several
observational cohort studies have been published report-
ing the endoscopic treatment of infected necrosis. Asmall randomised pilot trial has shown that endoscopic
necrosectomy is feasible and reduces the inflammatory
response, and possibly complications such as new onset
organ failure compared with surgical necrosectomy in
these often already critically ill patients [8]. Although ini-
tial results seem promising, a randomised controlled trial
with clinically relevant and applicable endpoints is needed
to compare the endoscopic and surgical step-up approach
in order to reach a sound evidence-based conclusion about
the superiority of either treatment modality.
Methods
Study objectives
The primary aim of this study is to investigate whether
an endoscopic step-up approach will reduce the combined
primary endpoint of death and major complications, as well
as the secondary endpoints, hospital stay and costs, as
compared to a surgical step-up approach in patients
with infected necrotising pancreatitis.
A secondary aim is to investigate whether endoscopic
transluminal drainage (ETD) is effective in preventing
necrosectomy.
Design
The TENSION trial is a randomised controlled, parallel-
group, superiority multicenter trial. Patients will be randomly
allocated using an internet-based randomisation program
(Academic Medical Center) to the endoscopic or surgical
step-up approach. Patients with (suspected) infected necrosis
are eligible for randomisation. The trial is registered in the
ISRCTN register (ISRCTN09186711).
Participating centers
Twenty-four hospitals of the Dutch Pancreatitis Study
Group (DPSG), including all Dutch university medical
centers, participate in the TENSION trial and will enrol pa-
tients (see Appendix for a list of all participating centers).
van Brunschot et al. BMC Gastroenterology 2013, 13:161 Page 3 of 13
http://www.biomedcentral.com/1471-230X/13/161Interventions will only take place in centers with sufficient
expertise and after the indication for intervention is sup-
ported by an online expert panel.Primary endpoint
The primary endpoint is a composite of death or major
complications occurring within 6 months following
randomisation.
Major complications are defined as new onset (i.e. not
present 24 hours before randomisation) organ failure
(cardiovascular, pulmonary or renal), bleeding requiring
intervention, perforation of a visceral organ requiring
intervention, enterocutaneous fistula requiring intervention
and incisional hernia (including burst abdomen) (see Table 1
for definitions).Secondary endpoints
 the individual components of the primary endpoint
 pancreaticocutaneous fistula (see Table 2 for
definitions)
 exocrine or endocrine pancreatic insufficiency
(see Table 2 for definitions)
 biliary strictures
 wound infections (see Table 2 for definitions)
 the need for necrosectomy (either endoscopically
or surgically)
 the need for additional radiological, endoscopic or
surgical interventions
 number of radiological, endoscopic and surgical (re-)
interventions
 total length of intensive care and hospital stay
 quality of life, quality adjusted life year’s (QALY’s,
with Short Form 36 and EQ5D)
 costs per patient with poor outcome and costs
per QALY
 total direct and indirect medical costs
 total number of cross-over between groupsTable 1 Primary endpoint: definitions
Event Definition
Organ failure Organ failure is defined as:
● Cardiovascular: systolic blood pressure < 90 mm
● Pulmonary: PaO2 < 60 mmHg despite FiO2 30%
● Renal: serum creatinine > 177 mmol/L after reh
Definitions are adapted from the Atlanta classific
New onset organ failure Organ failure occurring after randomisation and
Multiple organ failure Failure of 2 or more organ systems on the same
Enterocutaneous fistula Enterocutaneous fistula is defined as secretion of
removal of drains, or from a surgical wound, eith
Incisional hernia Incisional hernia is defined as a full-thickness disc
with or without obstruction [2]Study population
All patients admitted or transferred to one of the 24 partici-
pating hospitals of the DPSG with (suspected) infected ne-
crosis and an indication for intervention will be assessed
for eligibility. Patients (or their legal representatives) that
meet the in- and exclusion criteria will be asked for written
informed consent.
Inclusion criteria
 (Suspected) infected pancreatic and/or
extrapancreatic necrosis and an indication for
intervention [2,10] (see Table 3 for definitions).
 Both the endoscopic step-up approach and the
surgical step-up approach are technically feasible
 Age ≥ 18 years
Exclusion criteria
 Previous intervention (e.g. surgical, endoscopic or
percutaneous) for pancreatic necrosis,
extrapancreatic necrosis and/or peripancreatic
collections (see Table 3 for definitions)
 Acute flare up of chronic pancreatitis
 Indication for emergency laparotomy because of
suspected abdominal compartment syndrome,
bowel ischemia, bleeding or perforation of a
visceral organRandomisation
If a patient with pancreatic and/or extrapancreatic
necrosis shows clinical deterioration and has
reached the stage to decide on invasive intervention
for (suspected) infected necrosis, the Dutch nation-
wide expert panel is consulted. This panel, consist-
ing of 17 experts (9 surgeons, 4 gastroenterologists
and 4 radiologists) is available 24 hours a day,
7 days a week, to assess the indication for interven-
tion, the feasibility of both treatment options andHg despite adequate fluid resuscitation or need for vasopressor support
, or the need for mechanical ventilation;
ydration or need for hemofiltration or hemodialysis;
ation and the same as previously used in the PANTER trial [2]
not present 24 hours before randomisation
day
fecal material from a percutaneous drain, drainage canal after
er from small or large bowel; confirmed by imaging or during surgery [2]
ontinuity of the abdominal wall and bulging of abdominal contents,
Table 2 Secondary endpoint: definitions
Event Definition
Pancreaticocutaneous fistula Pancreaticocutaneous fistula is defined as output, through a percutaneous drain, drainage canal after removal
of drains, or from a surgical wound, of any measurable volume of fluid with an amylase content > 3 times the
serum amylase level
Pancreatic insufficiency ● Exocrine insufficiency is defined as an abnormal fecal elastase test or the need for oral pancreatic-enzyme
supplementation to treat clinical symptoms of steatorrhea (not present before onset pancreatitis)
● Endocrine insufficiency is defined as insulin or oral antidiabetic drugs required (not present before onset pancreatitis)
Wound infection [9] Wound infection is defined as a superficial incisional surgical site infection (SSI) and must meet the following criterion:
Infection occurs within 30 days after the operative procedure and involves only skin and subcutaneous
tissue of the incision and the patient has at least 1 of the following:
purulent drainage from the superficial/deep incision but not from the organ/space component of the surgical site
organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision
at least 1 of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat
the superficial incision is deliberately opened by surgeon and is culture positive or not cultured.
A culture-negative finding does not meet this criterion
an abscess or other evidence of infection involving the deep incision is found on direct examination,
during reoperation, or by histopathologic or radiologic examination
diagnosis of superficial/deep incisional SSI by the surgeon or attending physician
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vention is delayed to a phase of the disease at which
necrosis is walled-off, usually 3–4 weeks after onset. A
similar expert panel has already proven to be of value
during the previous Dutch PANTER and PENGUIN
trials [2,10]. After consultation of the expert panel, patients
eligible for inclusion are randomly assigned to group
A (endoscopic step-up approach, see Figure 1) or B
(surgical step-up approach, see Figure 2) as shown in the
flowcharts (Figures 3 and 4). Randomisation is performed
by the study coordinator using an internet-based ran-
domisation program (Academic Medical Center) ensuring
allocation concealment between groups. Randomisation is
stratified according to hospital.Table 3 Inclusion and exclusion criteria: definitions
Event Definition
Pancreatic necrosis Diffuse or focal area(s) of non-enhancin
Extrapancreatic necrosis Persistent peripancreatic fluid collection
(Suspected) infected necrosis ● Infected necrosis is defined as a posit
by fine-needle aspiration (FNA) or the p
● Suspected infected necrosis is defined
support on the intensive care unit (ICU)
documentation of infected necrosis and
Previous intervention Previous exploratory laparotomy for sus
bowel perforation is only allowed if the
MODS The Multiple Organ Dysfunction Score (
severe organ dysfunction
SOFA Scores on the Sequential Organ Failure
indicating more severe organ dysfunctioTreatment protocol
Group A (Endoscopic transluminal step-up approach)
Step 1: endoscopic transluminal drainage (ETD) Using
procedural sedation, with either i.v. administration of
midazolam and fentanyl or propofol, endoscopic ultrasound
guided transluminal drainage of the peripancreatic
collection is performed (see Figure 1). Two 7 Fr double
pigtail stents and a naso-cystic catheter are inserted
into the collection. The latter will be used for continuous
flushing with 1 liter saline/24 hours. In case of clinical im-
provement (see criteria below), subsequent necrosectomy is
avoided. In case a patient does not improve after 72 hours
and the collection is deemed inadequately drained as ob-
served on repeat CECT, additional drainage is performed.g pancreatic parenchyma as detected on contrast enhanced CT (CECT)
s on CECT in the absence of pancreatic parenchymal non-enhancement
ive culture of pancreatic necrosis or extrapancreatic necrosis obtained
resence of gas in the fluid collection on CECT.
as persistent sepsis or progressive clinical deterioration despite maximal
in case of pancreatic necrosis or extrapancreatic necrosis, without
without other causes for infection
pected abdominal compartment syndrome, bleeding or suspected
omental bursa was not opened
MODS) ranges from 0 to 24, with higher scores indicating more
Assessment (SOFA) scale range from 0 to 24, with higher scores
n
Figure 1 Endoscopic step-up approach. Endoscopic step-up approach consisting of endoscopic transluminal drainage (ETD) and endoscopic
transluminal necrosectomy (ETN). A large peripancreatic collection containing fluid and necrosis is shown. (A) ETD: the collection is punctured
through the gastric wall, followed by balloon dilatation of the tract. Two double-pigtail stents and a nasocystic catheter for continuous
postoperative irrigation are placed. (B) ETN: the cystostomy tract is dilated, the collection is entered with a endoscope, and necrosectomy is
performed. (Reprinted from van Brunschot et al. [11]; copyright 2013, with permission from Elsevier).
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in the fluid cavity), clinically unsuccessful or impossible,
the patient will proceed to step 2.
Step 2: endoscopic transluminal necrosectomy (ETN)
The cystogastrostomy is dilated up to 18 mm and the
cavity is entered with a therapeutic gastroscope to per-
form necrosectomy under direct endoscopic vision
(see Figure 1). The procedure is completed when most
loose adherent necrotic tissue is removed. Again two 7
Fr double pigtail stents and a naso-cystic catheter for
continuous lavage will be inserted into the collection.
The procedure is repeated in case there is no clinical
improvement within 72 hours.Group B (Surgical step-up approach)
This approach is similar to the step-up approach used in
the PANTER trial [2,10].
Step 1: percutaneous catheter drainage (PCD) A percu-
taneous 14 to 20 French drain is placed in the peripan-
creatic collection under guidance of CT or ultrasound
(see Figure 2). The preferred route is through the left
retroperitoneum, thereby facilitating video-assisted retro-
peritoneal débridement (VARD) [13] at a later stage if
needed. If this is not possible, trans-peritoneal drainage is
performed. Drains are kept open by flushing with 50 ml
saline three times daily. In case of clinical improvement,
the further effect of drainage is awaited. If a patient is not
Figure 2 Surgical step-up approach. Surgical step-up approach consisting of percutaneous catheter drainage (PCD) and video-assisted
retroperitoneal débridement (VARD). (A) Cross-sectional image and torso depicting a peripancreatic collection. The preferred route is through the
left retroperitoneal space between the kidney, spleen and descending colon. A percutaneous catheter drain is inserted in the collection to
mitigate sepsis and postpone or even obviate necrosectomy. The area of detail is shown in (B). (C) A 5 cm subcostal incision is made and the
percutaneous drain is followed into the collection. The first necrosis is removed under direct vision with a long grasping forceps, followed by
further debridement under videoscopic assistance (D). (Reprinted from van Brunschot et al. [11]; copyright 2013, with permission from Elsevier).
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on repeat CECT after 72 hours, additional drainage is
performed. If this is not possible, or if a second drainage is
clinically unsuccessful (see criteria for clinical improvement
below) the patient will proceed to step 2.
Step 2: video-assisted retroperitoneal debridement
(VARD, if not possible laparotomy) VARD is a drain-
guided, minimally invasive retroperitoneal procedure
requiring a 5 cm flank incision according to the previ-
ously published technique [13,14] (see Figure 2). Using
the retroperitoneal drain for guidance, the collection is
entered and only loosely adherent necrosis is removed
under video-assistance. At the end of the procedure
two large bore surgical drains are inserted. A continuous
post-operative lavage system (building up to 10 litres
saline per 24 hrs) is installed. In case of absence of
clinical improvement (see criteria below) and repeated
CECT shows foci of potentially inadequate drainage, VARD
is repeated. If VARD is technically not feasible, debridement
by laparotomy is performed.If drainage technically fails in the endoscopic group a
PCD is placed. In case of clinical or technical failure of
PCD, surgical necrosectomy is performed. Both approaches
are performed, according to a strict protocol, only in
participating centers with documented expertise and, if
necessary, under supervision of an expert. Sufficient
expertise is defined as having performed at least ten
independent VARD procedures or ten independent endo-
scopic transluminal drainage procedures and more than
five endoscopic transluminal necrosectomies. In case of
insufficient local experience, the patient is transferred to a
tertiary referral center with sufficient experience.
Criteria for clinical improvement
Criteria similar to the PANTER trial are used to define
clinical improvement, failure and to decide to go to the
next step [2,10]. Each step is evaluated 72 hours after
intervention and considered successful in case of clinical
improvement. Clinical improvement is defined as: improved
function of at least two organ systems (i.e. circulatory,
pulmonary, or renal) or improvement of two out of three
Figure 3 Flowchart TENSION trial according to CONSORT [12].
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or temperature). Clinical failure is defined as the absence
of clinical improvement or in case of clinical deterioration.
If there is, at evaluation or any moment thereafter, clinical
failure the next step or next necrosectomy is performed.
Deterioration by other infectious causes than infected
necrosis (e.g. a urinary tract infection) is excluded.General treatment regimen
All patients receive enteral nutrition. If oral feeding is
not tolerated or insufficient, a nasojejunal feeding tube
is introduced and enteral feeding is started. If the
required caloric intake cannot be reached via the enteral
route, the patient will receive (additional) parenteral
nutrition. All patients with (suspected) infected necrosis
will receive broad-spectrum antibiotic therapy according
to institutional protocols. Antibiotic treatment is tailored
based on blood cultures and culture from material collected
during drainage or surgical procedures. If cultures remain
negative, antibiotic treatment is stopped. Before retraction
or removal of a percutaneous drain or the pigtail stents the
remaining cavity is visualized.Data collection
Clinical data with regard to baseline characteristics and
outcome are collected during hospital admission using a
standardised case record form (CRF). An independent
monitor checks all endpoints and at least 10% of the CRF
data with on-site source data.
Follow-up
Patients are observed during their hospital stay. Outpatient
follow-up visits are scheduled at the discretion of the
responsible physician, but always 3 and 6 months after
randomisation and 3 and 6 months after discharge.
During these visits all patients will undergo a routine
CECT, exocrine and endocrine pancreatic function tests
(i.e. blood glucose measurements and fecal elastase test),
and receive a combined questionnaire (SF-36 [15], EQ-5D
[16], and Health and Labour [17]).
Safety
At regular intervals, an independent data safety and moni-
toring committee (DSMC) will evaluate the progress of the
trial and examine the unblinded safety variables [18]. All
physicians involved in the study will repetitively be asked
Figure 4 Flowchart treatment protocol TENSION trial.
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be listed and discussed with the DSMC. All possible
adverse events will also be reported to the Central
Committee on Research involving Human Subjects and
the institutional review board (IRB). Adverse events are
defined as ‘any undesirable experience occurring to a
subject during a clinical trial, whether or not considered
related to the intervention’. The outcome of the meeting
of the DSMC will be discussed with the trial steering
committee and sent to the IRB.
Ethics
The study is performed in accordance with the declaration
of Helsinki and the Dutch Medical Research Involving
Human Subjects Act. The IRB of the Academic Medical
Centre Amsterdam approved the protocol on the 31th
of January 2011. Secondary approval was sought from
all local ethics committees. Informed consent will be ob-
tained from each participating patient in oral and writtenform prior to randomisation. The TENSION trial is
registered in the ISRCTN register with identification
number ISRCTN09186711. After approval of the protocol,
no amendments on study design were made.
Statistical aspects
Sample size calculation
The TENSION trial is a superiority trial, hypothesizing
a reduction in the primary endpoint in favour of the
endoscopic step-up approach. Combined results of
published non-randomised studies on ETN were used
to calculate the sample size. These cohort studies show
that ETN results in a combined death and major com-
plication rate of 17% [19-24]. The previous randomised
PANTER trial showed a combined death and major
complication rate of 40% for the surgical step-up approach
[2]. Furthermore, in the surgical group an incisional hernia
rate of 7% was seen [2]. Assuming that some patients will
develop an incisional hernia in the surgical group without
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and major complications in this group, including incisional
hernias is estimated to be 43%. Therefore, an absolute
reduction in primary endpoint of 26% (from 43 to 17%)
is anticipated. With a 2-sided 5% alpha, power of 80%, and
2% loss to follow-up, the sample size was set at 98 patients.
Descriptive statistics
For dichotomous data, frequencies will be presented.
Continuous data will be presented as mean and standard
deviation or median and interquartile range. Baseline cri-
teria are: age, sex, body mass index, aetiology of pancrea-
titis, co-morbidity, American Society of Anaesthesiologist’s
(ASA) classification, CT severity index, extent of pancreatic
necrosis, disease severity (SIRS, ICU admission, single
or multiple organ failure), Acute Physiology and Chronic
Health Evaluation (APACHE) ll score, Imrie score, MODS
(Table 3), SOFA score (Table 3), C-reactive protein,
time from onset of symptoms to randomisation, tertiary
referral, and confirmed infected necrosis (bacterial culture
of first intervention).
Analyses
There will be a blinded outcome assessment after the last
patient completed follow-up for all primary and secondary
endpoints. Both intention-to-treat and per-protocol ana-
lyses will be performed. In intention-to-treat analysis, all
patients are analysed according to their initially assigned
study arm regardless of adherence to study protocol,
which is the primary analysis of the study. Occurrences
of the primary and secondary endpoints are compared
between treatment groups. Comparison of the primary
endpoint will be expressed in terms of a relative risk
and corresponding 95% confidence intervals. A two-
tailed P < 0.05 is considered statistically significant.
Subsequent analyses are directed at secondary end-
points. Predefined subgroup analysis will be performed
for patients with and without (multiple) organ failure
(see Table 1 for definitions) before randomisation, institution
and time between onset of symptoms and randomisation
(<28 or >28 days). A formal test of interaction in a logistic-
regression model is used to assess whether treatment effects
differ significantly between subgroups. In case of skewed
randomisation (i.e. statistically significant differences in
baseline variables), an adjusted analysis will be performed
using multivariable logistic regression.
Additional analyses
Direct and indirect medical and non-medical costs of both
treatment strategies for the follow-up period of 6 months
after randomisation will be compared. All costs will be
estimated based on the actual input in terms of resource
use (i.e. interventions, diagnostic procedures, hospital
and ICU stay), personnel, medication, visits to healthcareproviders, private household assistance, and indirect
costs from loss of productivity due to sick leave
(assessed with the Health and Labour questionnaire).
Total costs per patient are calculated by summing direct
medical costs, direct nonmedical costs, and indirect costs
and subsequently compared between groups. Furthermore,
the impact of differences in complications on the quality of
life is measured by a generic quality of life questionnaire,
the SF-36. In addition to this quality of life questionnaire,
the EQ-5D is completed which screens for the presence
and severity of problems with mobility, self-care, daily
activities, pain/complaints and mood.
Premature termination of the study
No formal interim-analysis is planned. To guarantee
patient’s safety throughout the study, the DSMC will
perform regular safety analyses. When harm (higher
incidence of SAE’s in one group) occurs, the DSMC
will discuss potential stopping of the trial prematurely
with the trial steering committee. Since this is the first
randomised trial comparing both approaches, and hence
all data arising from this trial, regardless of its outcome,
will influence treatment policy worldwide, the trial will
not be stopped for futility.
Discussion
The TENSION trial is designed to answer the question
whether an endoscopic step-up approach will lead to a
reduction of death and major complications compared to
a surgical step-up approach in patients with (suspected)
infected necrosis. The TENSION trial will also investigate
whether pancreatic fistula, exocrine or endocrine pancreatic
insufficiency, length of ICU and hospital stay, quality of life
and costs are reduced by the endoscopic step-up approach.
In recent years, minimally invasive approaches are grad-
ually replacing (primary) open necrosectomy. Minimally
invasive approaches aim at minimizing surgical stress and
have proven to reduce complications. In the PANTER
trial, the surgical step-up approach reduced the combined
death and major complication rate from 69% to 40% [2].
Furthermore, the PANTER trial showed that 35% of
patients with infected necrotising pancreatitis achieve
complete recovery after percutaneous drainage only,
without the need for surgical debridement. Although
the combined death and major complication rate is still
high, the surgical step-up approach should at present
be considered as the current standard of care worldwide
[2]. Drainage is based on the hypothesis that alleviating
pressure of an infected collection may improve the patient’s
clinical condition and thereby leaving the necrotic tissue
to be dealt with by the patient’s own immune system.
Endoscopic transluminal drainage can be applied accord-
ing to the same rationale. Therefore, we chose to institute
the step-up approach in both study arms. Due to the large
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not feasible. To partially compensate for this, outcome
assessment is blinded.
In the TENSION trial only patients with (suspected)
infected necrosis are included since the main indication
for intervention in necrotising pancreatitis is nowadays
considered to be infected necrosis [25-28]. Patients with
sterile necrosis can often be successfully managed conser-
vatively (i.e. without any form of intervention) [28-30].
A composite endpoint of death and major complications
was chosen because a study powered to demonstrate a
clinically relevant difference in death alone would require
an unrealistic large sample size of over 2000 patients.
In addition, previous studies have shown that major
complications have high impact in terms of quality of life
in patients with necrotising pancreatitis [2,8].
A potential limitation of the endoscopic approach is that
periprocedural complications (e.g. perforation or bleeding)
may be more difficult to manage when compared to peri-
procedural complications occurring during surgical necro-
sectomy. A systematic review and randomised trial have
suggested that endoscopic treatment of infected necrosis
is feasible and associated with lower or comparable com-
plication rates than surgery [7,8]. Furthermore, endoscopic
drainage and necrosectomy are advanced interventions
that not only require the expertise from an interventional
endoscopist, but also the dedicated involvement of inter-
ventional radiologists and pancreatic surgeons to manage
potential complications. For this reason the endoscopic in-
terventions in the TENSION trial will only be performed
in expert centers with multidisciplinary expertise.
Conclusion
The TENSION trial is a randomised controlled multicen-
ter trial designed to show a reduction in the composite
primary endpoint of death and major complications, as
well in hospital stay and costs following an endoscopic
transluminal step up approach compared with a surgi-
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